Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 51 studies | 51% ± 17% | |
macrophage | 30 studies | 29% ± 13% | |
classical monocyte | 21 studies | 24% ± 8% | |
non-classical monocyte | 20 studies | 38% ± 14% | |
plasma cell | 19 studies | 41% ± 16% | |
natural killer cell | 18 studies | 20% ± 4% | |
conventional dendritic cell | 16 studies | 25% ± 11% | |
capillary endothelial cell | 16 studies | 55% ± 12% | |
monocyte | 15 studies | 25% ± 7% | |
endothelial cell of artery | 14 studies | 46% ± 14% | |
dendritic cell | 13 studies | 30% ± 13% | |
ciliated cell | 13 studies | 31% ± 14% | |
endothelial cell of vascular tree | 13 studies | 43% ± 20% | |
vein endothelial cell | 12 studies | 39% ± 17% | |
microglial cell | 12 studies | 34% ± 12% | |
plasmablast | 11 studies | 43% ± 22% | |
CD16-negative, CD56-bright natural killer cell, human | 11 studies | 25% ± 9% | |
myeloid cell | 11 studies | 30% ± 10% | |
astrocyte | 11 studies | 35% ± 17% | |
B cell | 10 studies | 21% ± 7% | |
CD16-positive, CD56-dim natural killer cell, human | 10 studies | 22% ± 8% | |
platelet | 8 studies | 24% ± 4% | |
neutrophil | 8 studies | 31% ± 8% | |
endothelial cell of lymphatic vessel | 7 studies | 20% ± 4% | |
GABAergic neuron | 7 studies | 34% ± 16% | |
pericyte | 7 studies | 43% ± 27% | |
IgG plasma cell | 7 studies | 26% ± 7% | |
fibroblast | 7 studies | 18% ± 3% | |
gamma-delta T cell | 7 studies | 22% ± 5% | |
regulatory T cell | 7 studies | 19% ± 2% | |
IgA plasma cell | 6 studies | 28% ± 9% | |
glutamatergic neuron | 6 studies | 33% ± 15% | |
mature NK T cell | 5 studies | 20% ± 3% | |
kidney loop of Henle epithelial cell | 5 studies | 22% ± 5% | |
epithelial cell | 5 studies | 42% ± 24% | |
innate lymphoid cell | 5 studies | 22% ± 7% | |
oligodendrocyte | 5 studies | 29% ± 7% | |
squamous epithelial cell | 4 studies | 34% ± 21% | |
mononuclear phagocyte | 4 studies | 30% ± 4% | |
endothelial cell of sinusoid | 4 studies | 33% ± 13% | |
glomerular endothelial cell | 4 studies | 75% ± 3% | |
neuron | 4 studies | 26% ± 10% | |
mucosal invariant T cell | 4 studies | 19% ± 3% | |
naive B cell | 4 studies | 17% ± 1% | |
oligodendrocyte precursor cell | 4 studies | 25% ± 8% | |
basal cell | 4 studies | 32% ± 10% | |
interneuron | 4 studies | 40% ± 18% | |
abnormal cell | 4 studies | 23% ± 8% | |
ionocyte | 3 studies | 37% ± 7% | |
pancreatic A cell | 3 studies | 32% ± 17% | |
megakaryocyte | 3 studies | 45% ± 19% | |
memory B cell | 3 studies | 16% ± 0% | |
brush cell | 3 studies | 27% ± 9% | |
tissue-resident macrophage | 3 studies | 28% ± 7% | |
lymphocyte | 3 studies | 27% ± 8% | |
secretory cell | 3 studies | 44% ± 27% | |
germinal center B cell | 3 studies | 36% ± 10% | |
intermediate monocyte | 3 studies | 38% ± 16% | |
connective tissue cell | 3 studies | 19% ± 6% | |
leukocyte | 3 studies | 25% ± 3% | |
group 3 innate lymphoid cell | 3 studies | 31% ± 8% | |
plasmacytoid dendritic cell | 3 studies | 20% ± 4% | |
enteroendocrine cell | 3 studies | 27% ± 5% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 100% | 7362.72 | 2639 / 2642 | 100% | 57.55 | 705 / 705 |
esophagus | 100% | 4134.85 | 1438 / 1445 | 100% | 23.98 | 183 / 183 |
thymus | 100% | 7910.75 | 653 / 653 | 99% | 35.85 | 599 / 605 |
skin | 100% | 3910.76 | 1804 / 1809 | 99% | 42.71 | 468 / 472 |
kidney | 100% | 7103.49 | 89 / 89 | 99% | 50.21 | 890 / 901 |
breast | 100% | 11369.97 | 459 / 459 | 99% | 25.98 | 1104 / 1118 |
lung | 100% | 13403.51 | 578 / 578 | 98% | 28.28 | 1135 / 1155 |
stomach | 100% | 3981.79 | 359 / 359 | 98% | 19.39 | 281 / 286 |
intestine | 99% | 3728.32 | 960 / 966 | 98% | 18.20 | 515 / 527 |
prostate | 99% | 3831.63 | 243 / 245 | 98% | 23.19 | 491 / 502 |
uterus | 100% | 5066.68 | 170 / 170 | 97% | 22.43 | 443 / 459 |
adrenal gland | 100% | 10170.22 | 258 / 258 | 96% | 24.70 | 221 / 230 |
bladder | 100% | 4141.76 | 21 / 21 | 94% | 17.39 | 475 / 504 |
ovary | 99% | 3556.17 | 179 / 180 | 93% | 18.24 | 400 / 430 |
pancreas | 91% | 2321.16 | 300 / 328 | 98% | 28.12 | 174 / 178 |
liver | 42% | 927.80 | 95 / 226 | 77% | 10.13 | 312 / 406 |
adipose | 100% | 12896.72 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 46.40 | 29 / 29 |
muscle | 100% | 6031.84 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 9132.17 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 10.88 | 1 / 1 |
peripheral blood | 100% | 14747.20 | 928 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 99% | 20.12 | 79 / 80 |
heart | 99% | 4639.65 | 850 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 98% | 20.04 | 44 / 45 |
blood vessel | 90% | 3176.61 | 1206 / 1335 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0015871 | Biological process | choline transport |
GO_0039536 | Biological process | negative regulation of RIG-I signaling pathway |
GO_0045087 | Biological process | innate immune response |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0005794 | Cellular component | Golgi apparatus |
GO_0005737 | Cellular component | cytoplasm |
GO_0039552 | Molecular function | RIG-I binding |
GO_0140311 | Molecular function | protein sequestering activity |
GO_0005515 | Molecular function | protein binding |
Gene name | SEC14L1 |
Protein name | SEC14L1 protein SEC14 like lipid binding 1 SEC14 like lipid binding 1 (SEC14L1 protein) SEC14-like protein 1 |
Synonyms | SEC14L |
Description | FUNCTION: May play a role in innate immunity by inhibiting the antiviral RIG-I signaling pathway. In this pathway, functions as a negative regulator of RIGI, the cytoplasmic sensor of viral nucleic acids. Prevents the interaction of RIGI with MAVS/IPS1, an important step in signal propagation . May also regulate the SLC18A3 and SLC5A7 cholinergic transporters . . |
Accessions | K7EIJ7 ENST00000591786.5 ENST00000430767.8 [Q92503-1] K7ERB3 D5G3K4 K7EJ08 ENST00000589827.5 ENST00000431431.6 [Q92503-3] K7EQK4 ENST00000588488.1 ENST00000585618.5 [Q92503-1] ENST00000587820.1 ENST00000443798.8 [Q92503-2] ENST00000590483.1 K7EJJ2 ENST00000588880.5 ENST00000591437.5 [Q92503-3] ENST00000561721.6 ENST00000589202.1 ENST00000588616.6 K7EPE4 K7ESI4 A5PLM6 K7ELM0 Q92503 ENST00000436233.9 [Q92503-1] ENST00000392476.6 [Q92503-2] K7ELU0 ENST00000586429.5 D5G3K3 |